University of Notre Dame and Kraig Biocraft Laboratories to Hold Joint Press Conference
LANSING, Mich., September 24, 2010 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that the University of Notre Dame and Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.
The press conference will take place in the University of Notre Dame's Jordan Hall of Science at 11:00 A.M. Due to space limitations, media only please. For invitations and further details the media are invited to contact Ben Hansel (720) 288-8495.
For more information on Kraig Biocraft Laboratories please visit the Company's web site: https://kraiglabs.com
Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
CONTACT: Ben Hansel (720) 288-8495 firstname.lastname@example.org